MDxHealth to Present Results from Epigenetic Prostate Test to Identify Aggressive Prostate Cancer at the ASCO Genitourinary Cancers Symposium 2014

IRVINE, CA, and HERSTAL, BELGIUM – January 29, 2014 – MDxHealth SA (NYSE Euronext: MDXH), a leading molecular diagnostic company that develops and commercializes epigenetic tests to improve the diagnosis and treatment of cancer patients, today announced that the company will present results from an important study involving the development of their prostate cancer (PCa) aggressiveness test at the ASCO Genitourinary Cancers Symposium 2014 in San Francisco, California, USA (January 30 - February 1, 2014).

In current standard medical practice PCa prognosis and aggressiveness are mainly guided by Gleason score (GS), as determined on biopsied tissue. However, due to sampling errors biopsied prostate tissue might not be representative of the actual disease. MDxHealth is currently developing an epigenetic prostate cancer test to identify men with aggressive disease and adverse prognosis.

Details of presentation (time is Pacific Standard Time):

**Friday, January 31, 2014**

**Abstract Title:** Epigenetic profiling of prostate cancer tissue identifies men with high risk disease.

**Lead Author:** Leander Van Neste PhD, Maastricht University, Dept. of Pathology, GROW - School for Oncology and Developmental Biology, Maastricht, The Netherlands

**Location:** General poster session B: BRD.A1 (abstract 197)

**Time:** 12:00pm-1:30pm and 5:45pm-7:15pm

**About MDxHealth®**

MDxHealth is a molecular diagnostics company that develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company’s first commercial product, ConfirmMDx™ for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth helps to address a large and growing unmet medical need for better cancer diagnosis and treatment information. The company has a proprietary platform and a strong epigenetic product pipeline focused on the development of products for prostate, brain and lung cancers. The company is based in Irvine, California with a European headquarters in Herstal, Belgium. For more information visit MDxHealth’s website at [www.mdxhealth.com](http://www.mdxhealth.com) and follow us on Twitter at: twitter.com/mdxhealth.
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company’s control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.

NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.